<DOC>
	<DOCNO>NCT00313937</DOCNO>
	<brief_summary>Primary objective : To compare metabolic control measure Blood Glucose ( BG ) upon arise bed ( 7:00 - 12:00 pm ) type 1 Diabetes mellitus patient skip morning meal treatment MDI basal/bolus insulin : Difference change blood glucose 7:00 11:00 patient Insulin glargine NPH insulin . Secondary objective : To perform evaluation two patient group BG ( 10:00 pm 12:00 pm ) well serum insulin , free fatty acid level Î²-hydroxybutyrate ( 7:00 - 12:00 pm ) .</brief_summary>
	<brief_title>SAM - Skip Meal - Insulin Glargine , Diabetes Mellitus Type 1</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 1 Diabetes mellitus treat MDI ( Multiple Daily Injection ) basal/bolus insulin , regular insulin/short act insulin analogue + NPH insulin stable dose ( change 10 % ) least 4 week prior study entry , HBA1c smaller/equal 9 % ( measure visit 1 ) BMI smaller/equal 35 kg/m2 . In addition , patient must FBG value day 1 skip meal ( 6:00 07:00 ) 90 120 mg/dl ( 5.0 6.5 mmol/l ) . Breastfeeding History hypersensitivity study medication drug similar chemical structure Likelihood require treatment study period drug permit study protocol Treatment investigational drug last 30 day study entry Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult History drug alcohol abuse No subject previously treat Insulin glargine enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>